PW01-20 - Adjunctive aripiprazole in patients with major depressive disorder: pooled safety and tolerability data from three short-term studies

Conclusions In this pooled analysis of patients with MDD and an inadequate response to ADT, adjunctive aripiprazole showed consistently high study completion rates and low discontinuation rates resulting from adverse events.